A Phase 4 interventional study of VACCINE: placebo and VACCINE: 13-valent pneumococcal conjugate vaccine in Pneumonia, Pneumococcal, Pneumococcal Infections and 13-valent Pneumococcal Vaccine, sponsored by Pfizer. Completed at 159 sites in Netherlands. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-06.
Sponsored by Pfizer · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.
44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.
This study's enrollment of 84,496 is above the median of 388 across 37 interventional studies indexed under Pneumonia, Pneumococcal.
Browse Pneumonia, Pneumococcal studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: VACCINE: placebo
Biological: VACCINE: 13-valent pneumococcal conjugate vaccine
0.5 mL, single intra-muscular injection
0.5 mL, single intra-muscular injection
Also known as: 13vPnC
Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP)
CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature greater than (\>) 38.0 degrees Celsius (C) or less than (\<) 36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (\>10\*10\^9 white blood cells/liter or \>15 percent (%) bands), C-reactive protein level \>3 times upper limit of normal, hypoxemia with partial oxygen pressure \<60 millimeter of mercury (mmHg). Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: VT Streptococcus pneumonia culture from blood, pleural fluid or other sterile site and/or positive VT serotype-specific urinary antigen detection (SSUAD).
Time frame: Baseline up to occurrence of first episode of VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)
Number of Participants With First Episode of Nonbacteremic/Noninvasive (NB/NI) Vaccine-type Community-acquired Pneumonia (VT-CAP)
CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature \>38.0 degrees C or \<36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (\>10\*10\^9 white blood cells/liter or \>15% bands), C-reactive protein level \>3 times upper limit of normal, hypoxemia with partial oxygen pressure \<60 mmHg. Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: Confirmed VT pneumococcal CAP (by SSUAD) where a blood culture result was available and was negative and for which any other sterile culture results were negative for Streptococcus pneumoniae.
Time frame: Baseline up to occurrence of first episode of NB/NI VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)
Number of Participants With First Episodes of Vaccine-type Invasive Pneumococcal Disease (VT-IPD) Cases
VT-IPD was defined as the presence of Streptococcus pneumoniae in a sterile site (blood, cerebrospinal fluid, pleural fluid, peritoneal fluid, pericardial fluid, surgical aspirate, bone, or joint fluid).
Time frame: Baseline up to occurrence of first episode of VT-IPD, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)
Percentage of Participants With Pre-specified Local Reactions Within 7 Days After Vaccination
Local reactions were reported using electronic diary (e-diary). Redness and swelling scaled as Any (redness or swelling present); Absent (no or minimal); Mild (2.5 centimeter \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Limitation of arm movement scaled as Any (limitation present); Absent (no limitation of arm movement); Mild (some limitation of arm movement); Moderate (unable to move arm above head, but able to move arm above shoulder); Severe (unable to move arm above shoulder). Percentage of participants with local reactions were reported. Participants may be represented in more than 1 category.
Time frame: Within 7 days after vaccination
Percentage of Participants With Pre-specified Systemic Events Within 7 Days After Vaccination
Systemic events (fever, fatigue, headache, chills, rash, vomiting, decreased appetite, diarrhea, new generalized muscle/joint pain \[new muscle/joint pain\], aggravated generalized muscle/joint pain \[aggravated muscle/joint pain\], use of medication to treat pain/fever) reported using an e-diary. Fever scaled as Absent(\<38 degrees C); Mild(greater than or equal to \[\>=\]38 to \<38.5 degrees C); Moderate(\>=38.5 to \<39 degrees C); Severe(\>=39 to less than or equal to \[\<=\]40 degrees C); Potentially life threatening (\>40 degrees C). Fatigue, headache, new/aggravated muscle/joint pain scaled as Mild(no interference); Moderate(some interference); Severe(prevented routine activity). Vomiting scaled as Mild(1-2 times in 24 hours \[hrs\]); Moderate(\>2 times in 24 hrs); Severe(required intravenous hydration). Diarrhea scaled as Mild(2-3 loose stools in 24 hrs); Moderate(4-5 loose stools in 24 hrs); Severe(\>=6 loose stools in 24 hrs). Percentage of participants with systemic events were reported.
Time frame: Within 7 days after vaccination
Percentage of Participants Who Died
Deaths collected throughout the case acquisition period were presented.
Time frame: From signing of informed consent form up to case acquisition period defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)
Percentage of Participants With Newly Diagnosed Chronic Medical Condition
Percentage of participants with newly diagnosed chronic medical conditions (including autoimmune or neuroinflammatory disease) in the immunogenicity subset were reported as per planned analysis.
Time frame: From 1 month after vaccination up to 6 months after vaccination
Of 84496 participants who were randomized in this study, 2011 participants were included in the immunogenicity subset. Participants in the immunogenicity subset were analyzed for local reactions and systemic events as per planned analysis.
| Milestone | 13vPnC | Placebo |
|---|---|---|
| Started | 42240 | 42256 |
| Completed | 37004 | 36936 |
| Not completed | 5236 | 5320 |
| Withdrew: Death | 3006 | 3005 |
| Withdrew: Lost to follow-up | 2038 | 2135 |
| Withdrew: Withdrawal by subject | 166 | 150 |
| Withdrew: Physician decision | 20 | 23 |
| Withdrew: Protocol violation | 3 | 5 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Other | 2 | 2 |
CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature greater than (\>) 38.0 degrees Celsius (C) or less than (\<) 36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (\>10\*10\^9 white blood cells/liter or \>15 percent (%) bands), C-reactive protein level \>3 times upper limit of normal, hypoxemia with partial oxygen pressure \<60 millimeter of mercury (mmHg). Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: VT Streptococcus pneumonia culture from blood, pleural fluid or other sterile site and/or positive VT serotype-specific urinary antigen detection (SSUAD).
| participants | 13vPnC | Placebo |
|---|---|---|
| Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP) | 49 | 90 |
CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature \>38.0 degrees C or \<36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (\>10\*10\^9 white blood cells/liter or \>15% bands), C-reactive protein level \>3 times upper limit of normal, hypoxemia with partial oxygen pressure \<60 mmHg. Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: Confirmed VT pneumococcal CAP (by SSUAD) where a blood culture result was available and was negative and for which any other sterile culture results were negative for Streptococcus pneumoniae.
| participants | 13vPnC | Placebo |
|---|---|---|
| Number of Participants With First Episode of Nonbacteremic/Noninvasive (NB/NI) Vaccine-type Community-acquired Pneumonia (VT-CAP) | 33 | 60 |
VT-IPD was defined as the presence of Streptococcus pneumoniae in a sterile site (blood, cerebrospinal fluid, pleural fluid, peritoneal fluid, pericardial fluid, surgical aspirate, bone, or joint fluid).
| participants | 13vPnC | Placebo |
|---|---|---|
| Number of Participants With First Episodes of Vaccine-type Invasive Pneumococcal Disease (VT-IPD) Cases | 7 | 28 |
Local reactions were reported using electronic diary (e-diary). Redness and swelling scaled as Any (redness or swelling present); Absent (no or minimal); Mild (2.5 centimeter \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\>10.0 cm). Pain scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Limitation of arm movement scaled as Any (limitation present); Absent (no limitation of arm movement); Mild (some limitation of arm movement); Moderate (unable to move arm above head, but able to move arm above shoulder); Severe (unable to move arm above shoulder). Percentage of participants with local reactions were reported. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC | Placebo |
|---|---|---|
| Redness: Any (n = 886, 859) | 4.9 (3.5 to 6.5) | 1.2 (0.6 to 2.1) |
| Redness: Mild (n = 886, 859) | 3.7 (2.6 to 5.2) | 0.8 (0.3 to 1.7) |
| Redness: Moderate (n = 881, 859) | 1.7 (1.0 to 2.8) | 0.3 (0.1 to 1.0) |
| Redness: Severe (n = 881, 859) | 0.5 (0.1 to 1.2) | 0.1 (0.0 to 0.6) |
| Swelling: Any (n = 888, 859) | 6.8 (5.2 to 8.6) | 1.2 (0.6 to 2.1) |
| Swelling: Mild (n = 888, 859) | 5.5 (4.1 to 7.2) | 0.7 (0.3 to 1.5) |
| Swelling: Moderate (n = 884, 859) | 2.6 (1.7 to 3.9) | 0.6 (0.2 to 1.4) |
| Swelling: Severe (n = 881, 859) | 0.1 (0.0 to 0.6) | 0.1 (0.0 to 0.6) |
| Pain: Any (n = 914, 863) | 36.1 (33.0 to 39.3) | 6.1 (4.6 to 8.0) |
| Pain: Mild (n = 913, 861) | 32.9 (29.8 to 36.0) | 5.6 (4.1 to 7.3) |
| Pain: Moderate (n = 886, 860) | 7.7 (6.0 to 9.6) | 0.6 (0.2 to 1.4) |
| Pain: Severe (n = 881, 860) | 0.3 (0.1 to 1.0) | 0.1 (0.0 to 0.6) |
| Limitation of arm movement: Any (n = 891, 865) | 14.1 (11.9 to 16.6) | 3.2 (2.2 to 4.6) |
| Limitation of arm movement: Mild (n = 888, 863) | 12.4 (10.3 to 14.7) | 2.5 (1.6 to 3.8) |
| Limitation of arm movement: Moderate (n =883, 860) | 1.7 (1.0 to 2.8) | 0.5 (0.1 to 1.2) |
| Limitation of arm movement: Severe (n = 882, 861) | 1.2 (0.6 to 2.2) | 0.7 (0.3 to 1.5) |
Systemic events (fever, fatigue, headache, chills, rash, vomiting, decreased appetite, diarrhea, new generalized muscle/joint pain \[new muscle/joint pain\], aggravated generalized muscle/joint pain \[aggravated muscle/joint pain\], use of medication to treat pain/fever) reported using an e-diary. Fever scaled as Absent(\<38 degrees C); Mild(greater than or equal to \[\>=\]38 to \<38.5 degrees C); Moderate(\>=38.5 to \<39 degrees C); Severe(\>=39 to less than or equal to \[\<=\]40 degrees C); Potentially life threatening (\>40 degrees C). Fatigue, headache, new/aggravated muscle/joint pain scaled as Mild(no interference); Moderate(some interference); Severe(prevented routine activity). Vomiting scaled as Mild(1-2 times in 24 hours \[hrs\]); Moderate(\>2 times in 24 hrs); Severe(required intravenous hydration). Diarrhea scaled as Mild(2-3 loose stools in 24 hrs); Moderate(4-5 loose stools in 24 hrs); Severe(\>=6 loose stools in 24 hrs). Percentage of participants with systemic events were reported.
| percentage of participants | 13vPnC | Placebo |
|---|---|---|
| Fever: >=38 to <38.5 degrees C (n = 883, 859) | 1.1 (0.5 to 2.1) | 0.6 (0.2 to 1.4) |
| Fever: >=38.5 to <39 degrees C (n = 881, 859) | 0.6 (0.2 to 1.3) | 0.2 (0.0 to 0.8) |
| Fever: >=39 to =<40 degrees C (n = 882, 859) | 0.7 (0.3 to 1.5) | 0.2 (0.0 to 0.8) |
| Fever: >40 degrees C (n = 882, 860) | 0.8 (0.3 to 1.6) | 0.3 (0.1 to 1.0) |
| Fatigue: Mild (n = 892, 871) | 13.8 (11.6 to 16.2) | 11.7 (9.7 to 14.0) |
| Fatigue: Moderate (n = 886, 866) | 7.8 (6.1 to 9.8) | 6.2 (4.7 to 8.1) |
| Fatigue: Severe (n = 883, 863) | 1.4 (0.7 to 2.4) | 0.9 (0.4 to 1.8) |
| Headache: Mild (n = 891, 870) | 13.0 (10.9 to 15.4) | 13.1 (10.9 to 15.5) |
| Headache: Moderate (n = 883, 868) | 5.2 (3.8 to 6.9) | 3.8 (2.6 to 5.3) |
| Headache: Severe (n = 881, 861) | 0.6 (0.2 to 1.3) | 0.6 (0.2 to 1.3) |
| Chills (n = 891, 866) | 9.4 (7.6 to 11.5) | 8.4 (6.7 to 10.5) |
| Rash (n = 882, 860) | 3.3 (2.2 to 4.7) | 0.8 (0.3 to 1.7) |
| Vomiting: Mild (n = 881, 860) | 0.0 (0.0 to 0.4) | 0.7 (0.3 to 1.5) |
| Vomiting: Moderate (n =881, 860) | 0.1 (0.0 to 0.6) | 0.1 (0.0 to 0.6) |
| Vomiting: Severe (n = 881, 860) | 0.2 (0.0 to 0.8) | 0.1 (0.0 to 0.6) |
| Decreased appetite (n = 886, 865) | 5.3 (3.9 to 7.0) | 3.7 (2.5 to 5.2) |
| Diarrhea: Mild (n = 887, 868) | 5.1 (3.7 to 6.7) | 7.7 (6.0 to 9.7) |
| Diarrhea: Moderate (n = 882, 863) | 1.2 (0.6 to 2.2) | 1.0 (0.5 to 2.0) |
| Diarrhea: Severe (n = 881, 862) | 0.7 (0.3 to 1.5) | 0.5 (0.1 to 1.2) |
| New muscle pain: Mild (n = 894, 865) | 14.5 (12.3 to 17.0) | 6.7 (5.1 to 8.6) |
| New muscle pain: Moderate (n = 886, 863) | 5.9 (4.4 to 7.6) | 2.8 (1.8 to 4.1) |
| New muscle pain: Severe (n = 882, 860) | 0.7 (0.3 to 1.5) | 0.5 (0.1 to 1.2) |
| Aggravated muscle pain: Mild (n = 886, 862) | 4.6 (3.3 to 6.2) | 1.9 (1.1 to 3.0) |
| Aggravated muscle pain: Moderate (n = 885, 863) | 5.1 (3.7 to 6.7) | 2.8 (1.8 to 4.1) |
| Aggravated muscle pain: Severe (n = 882, 860) | 0.7 (0.3 to 1.5) | 0.1 (0.0 to 0.6) |
| New joint pain: Mild (n = 884, 862) | 5.0 (3.6 to 6.6) | 3.9 (2.7 to 5.5) |
| New joint pain: Moderate (n = 883, 864) | 2.9 (1.9 to 4.3) | 2.2 (1.3 to 3.4) |
| New joint pain: Severe (n = 882, 860) | 0.3 (0.1 to 1.0) | 0.3 (0.1 to 1.0) |
| Aggravated joint pain: Mild (n = 883, 861) | 2.3 (1.4 to 3.5) | 1.7 (1.0 to 2.9) |
| Aggravated joint pain: Moderate (n = 884, 862) | 3.2 (2.1 to 4.5) | 2.6 (1.6 to 3.8) |
| Aggravated joint pain: Severe (n = 882, 860) | 0.3 (0.1 to 1.0) | 0.3 (0.1 to 1.0) |
| Use of medication to treat pain (n = 887, 872) | 8.0 (6.3 to 10.0) | 6.2 (4.7 to 8.0) |
| Use of medication to treat fever (n = 883, 863) | 3.2 (2.1 to 4.6) | 1.5 (0.8 to 2.6) |
Deaths collected throughout the case acquisition period were presented.
| percentage of participants | 13vPnC | Placebo |
|---|---|---|
| Percentage of Participants Who Died | 7.1 | 7.1 |
Percentage of participants with newly diagnosed chronic medical conditions (including autoimmune or neuroinflammatory disease) in the immunogenicity subset were reported as per planned analysis.
| percentage of participants | 13vPnC | Placebo |
|---|---|---|
| Percentage of Participants With Newly Diagnosed Chronic Medical Condition | 1.7 | 1.2 |
Collected over Safety set (SAEs: Day 1 up to 1 month after vaccination); Immunogenicity subset (SAEs:1 month up to 6 month after vaccination; Other AEs: Day 1 up to 1 month after vaccination; pre-specified local reactions, systemic events:up to 7 days after vaccination). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Safety Set | — | 327/42,237 (0.8%) | — |
| Placebo Safety Set | — | 314/42,255 (0.7%) | — |
| 13vPnC Immunogenicity Subset | — | 55/1,006 (5.5%) | 363/1,006 (36.1%) |
| Placebo Immunogenicity Subset | — | 48/1,005 (4.8%) | 315/1,005 (31.3%) |
| Event | 13vPnC Safety Set | Placebo Safety Set | 13vPnC Immunogenicity Subset | Placebo Immunogenicity Subset |
|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/42237 | 0/42255 | 2/1006 | 10/1005 |
| Cardiac failureCardiac disorders | 7/42237 | 10/42255 | 4/1006 | 0/1005 |
| PneumoniaInfections and infestations | 14/42237 | 6/42255 | 4/1006 | 1/1005 |
| Angina pectorisCardiac disorders | 19/42237 | 19/42255 | 3/1006 | 1/1005 |
| Atrial fibrillationCardiac disorders | 13/42237 | 9/42255 | 3/1006 | 1/1005 |
| Cerebrovascular accidentNervous system disorders | 9/42237 | 8/42255 | 3/1006 | 1/1005 |
| Ankle fractureInjury, poisoning and procedural complications | 2/42237 | 1/42255 | 0/1006 | 2/1005 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/42237 | 7/42255 | 0/1006 | 2/1005 |
| Wound infectionInfections and infestations | 0/42237 | 2/42255 | 2/1006 | 1/1005 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/42237 | 0/42255 | 2/1006 | 1/1005 |
| Event | 13vPnC Safety Set | Placebo Safety Set | 13vPnC Immunogenicity Subset | Placebo Immunogenicity Subset |
|---|---|---|---|---|
| Pain: AnySkin and subcutaneous tissue disorders | — | — | 330/914 | 53/863 |
| Pain: MildSkin and subcutaneous tissue disorders | — | — | 300/913 | 48/861 |
| New generalized muscle pain: MildGeneral disorders | — | — | 130/894 | 58/865 |
| Limitation of arm movement: AnySkin and subcutaneous tissue disorders | — | — | 126/891 | 28/865 |
| Fatigue: MildGeneral disorders | — | — | 123/892 | 102/871 |
| Headache: MildGeneral disorders | — | — | 116/891 | 114/870 |
| Limitation of arm movement: MildSkin and subcutaneous tissue disorders | — | — | 110/888 | 22/863 |
| ChillsGeneral disorders | — | — | 84/891 | 73/866 |
| Fatigue: ModerateGeneral disorders | — | — | 69/886 | 54/866 |
| Diarrhea: MildGeneral disorders | — | — | 45/887 | 67/868 |
Safety population included all participants who received study vaccine and who had any safety data.
| Age, Continuous(years) | 13vPnC | Placebo | Total |
|---|---|---|---|
| Mean | 72.8 ± 5.7 | 72.8 ± 5.6 | 72.8 ± 5.7 |
| Sex: Female, Male(Participants) | 13vPnC | Placebo | Total |
|---|---|---|---|
| Female | 18790 | 18454 | 37244 |
| Male | 23447 | 23801 | 47248 |
Showing the first 100 of 159 sites. Choose a country and city above to see the rest.
The record gives a start of Sep 2008, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine